184 related articles for article (PubMed ID: 26443804)
21. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
Onda M; Nagata S; FitzGerald DJ; Beers R; Fisher RJ; Vincent JJ; Lee B; Nakamura M; Hwang J; Kreitman RJ; Hassan R; Pastan I
J Immunol; 2006 Dec; 177(12):8822-34. PubMed ID: 17142785
[TBL] [Abstract][Full Text] [Related]
22. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Fan D; Yano S; Shinohara H; Solorzano C; Van Arsdall M; Bucana CD; Pathak S; Kruzel E; Herbst RS; Onn A; Roach JS; Onda M; Wang QC; Pastan I; Fidler IJ
Mol Cancer Ther; 2002 Jun; 1(8):595-600. PubMed ID: 12479219
[TBL] [Abstract][Full Text] [Related]
24. Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line.
Hollevoet K; Mason-Osann E; Müller F; Pastan I
PLoS One; 2015; 10(3):e0122462. PubMed ID: 25803818
[TBL] [Abstract][Full Text] [Related]
25. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
26. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
[TBL] [Abstract][Full Text] [Related]
27. Fusion protein vaccine by domains of bacterial exotoxin linked with a tumor antigen generates potent immunologic responses and antitumor effects.
Liao CW; Chen CA; Lee CN; Su YN; Chang MC; Syu MH; Hsieh CY; Cheng WF
Cancer Res; 2005 Oct; 65(19):9089-98. PubMed ID: 16204084
[TBL] [Abstract][Full Text] [Related]
28. Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.
Ali-Rahmani F; FitzGerald DJ; Martin S; Patel P; Prunotto M; Ormanoglu P; Thomas C; Pastan I
Cancer Res; 2016 Mar; 76(6):1560-8. PubMed ID: 26719540
[TBL] [Abstract][Full Text] [Related]
29. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models.
Scales SJ; Gupta N; Pacheco G; Firestein R; French DM; Koeppen H; Rangell L; Barry-Hamilton V; Luis E; Chuh J; Zhang Y; Ingle GS; Fourie-O'Donohue A; Kozak KR; Ross S; Dennis MS; Spencer SD
Mol Cancer Ther; 2014 Nov; 13(11):2630-40. PubMed ID: 25249555
[TBL] [Abstract][Full Text] [Related]
30. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Onda M; Kobayashi K; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
[TBL] [Abstract][Full Text] [Related]
31. Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Leshem Y; O'Brien J; Liu X; Bera TK; Terabe M; Berzofsky JA; Bossenmaier B; Niederfellner G; Tai CH; Reiter Y; Pastan I
Cancer Immunol Res; 2017 Aug; 5(8):685-694. PubMed ID: 28674083
[TBL] [Abstract][Full Text] [Related]
32. Modulating mesothelin shedding to improve therapy.
Pastan I; Zhang Y
Oncotarget; 2012 Feb; 3(2):114-5. PubMed ID: 22337812
[No Abstract] [Full Text] [Related]
33. Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A-Based Immunotoxins.
Liu X; Müller F; Wayne AS; Pastan I
Mol Cancer Ther; 2016 May; 15(5):1053-62. PubMed ID: 26939705
[TBL] [Abstract][Full Text] [Related]
34. Removing T-cell epitopes with computational protein design.
King C; Garza EN; Mazor R; Linehan JL; Pastan I; Pepper M; Baker D
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8577-82. PubMed ID: 24843166
[TBL] [Abstract][Full Text] [Related]
35. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
[TBL] [Abstract][Full Text] [Related]
36. Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.
Mazor R; Kaplan G; Park D; Jang Y; Lee F; Kreitman R; Pastan I
Cell Immunol; 2017 Mar; 313():59-66. PubMed ID: 28087047
[TBL] [Abstract][Full Text] [Related]
37. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
38. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.
Baiz D; Hassan S; Choi YA; Flores A; Karpova Y; Yancey D; Pullikuth A; Sui G; Sadelain M; Debinski W; Kulik G
Neoplasia; 2013 Oct; 15(10):1172-83. PubMed ID: 24204196
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
40. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA' in a human acute myeloid leukemia xenograft tumor model.
Tur MK; Huhn M; Jost E; Thepen T; Brümmendorf TH; Barth S
Int J Cancer; 2011 Sep; 129(5):1277-82. PubMed ID: 21077160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]